Before we go onto the news of the day allow us to finish up on Abbott. Other than learning that Libre2 is aways away we also asked why the company continued to invest in Bigfoot. Here as well the answer was somewhat confusing as the company noted they like the Bigfoot platform but in the same answer pointed out there other partnerships with the insulin companies. Now to us this seems almost counter intuitive as if the Bigfoot platform is so good why also partner with the insulin companies who are developing Tyler’s of their own and who as . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.